Pubblicazioni

Proprotein convertase subtilisin kexin type 9 inhibitors reduce platelet activation modulating ox-LDL pathways

2021 - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Cammisotto, V.; Baratta, F.; Castellani, V.; Bartimoccia, S.; Nocella, C.; D'erasmo, L.; Cocomello, N.; Barale, C.; Scicali, R.; Di Pino, A.; Piro, S.; Del Ben, M.; Arca, M.; Russo, I.; Purrello, F.; Carnevale, R.; Violi, F.; Pastori, D.; Pignatelli, P.

Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile

2021 - ATHEROSCLEROSIS PLUS

Lupo, Maria Giovanna; Arcidiacono, Diletta; Zaramella, Alice; Fimiani, Fabio; CalabrÃ², Paolo; CefalÃ¹, Angelo Baldassare; Averna, Maurizio; D'Erasmo, Laura; Arca, Marcello; De Martin, Sara; Zambon, Alberto; Ferri, Nicola

Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolaemia

2016 - EUROPEAN HEART JOURNAL

Kees Hovingh, G.; Raal, Frederick J.; Dent, Ricardo; Stefanutti, Claudia; Descamps, Olivier; Lira, Armando; Bridges, Ian; Somaratne, Ransi; Sullivan, David